Study Group 1 for Retinitis Pigmentosa
CHNO XV-XX Paris - CIC 1423, Paris, France
Ophthalmic examinations +1 moreN/AWaitlist AvailableLed by Saddek Mohand-Saïd, MD, PhDResearch Sponsored by SparingVisionEligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Must not have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up1 year
Awards & highlights
No Placebo-Only Group
Study Summary
This trial is looking at the effects of different mutations that cause Retinitis Pigmentosa, a degenerative disease of the retina.
Eligible Conditions
- Retinitis Pigmentosa
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Fundus Autofluorescence (FAF)
Spectral Domain Optical Coherence tomography (SD-OCT)
Secondary outcome measures
Color vision
Dark adaptometry (DA)
Full-field stimulus threshold (FST)
+2 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: Study Group 2Experimental Treatment2 Interventions
Four years follow-up of patients with ophthalmic examination and mobility testing.
Group II: Study Group 1Experimental Treatment1 Intervention
Four years follow up of patients with ophthalmic examination.
Find a site
Who is running the clinical trial?
SparingVisionLead Sponsor
2 Previous Clinical Trials
146 Total Patients Enrolled
2 Trials studying Retinitis Pigmentosa
146 Patients Enrolled for Retinitis Pigmentosa
Saddek Mohand-Saïd, MD, PhDPrincipal Investigator
CHNO XV-XX Paris - CIC 1423Isabelle Audo, MD, PhDPrincipal Investigator
CHNO XV-XX Paris - CIC 1423Media Library
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
What ultimate goal is this medical research aiming to attain?
"This clinical study, lasting approximately 12 months, will measure the progression of disease over time through Fundus Autofluorescence (FAF), Dark Adaptometry (DA) refraction and visual acuity using ETDRS or Snellen scales as well as Full-field Stimulus Thresholds (FST)."
Answered by AI
Is this experiment still recruiting participants?
"According to clinicaltrials.gov, this particular medical study is not currently recruiting participants; the trial was initially posted on February 12th 2020 and last updated on April 19th 2022. Despite this fact, there are 51 other research initiatives that are actively enrolling patients at present."
Answered by AI